Skip to content
Crime, Medical Health Aged Care

NSW court diversion program for alcohol and other drugs use lowers rates of reoffending and imprisonment, new study finds

National Drug and Alcohol Research Centre (NDARC) 3 mins read
  • Media:

Defendants in NSW who complete a 12-week voluntary treatment program for alcohol and other drugs (AOD) use are much less likely to reoffend or receive a prison sentence, a landmark evaluation shows.

The findings, published in the International Journal of Drug Policy, provide strong evidence to support the pre-plea Magistrates Early Referral into Treatment (MERIT) program for adults facing charges in the NSW Local Court.

“This study is proof that MERIT is effective in reducing the short-term risk of reoffending, imprisonment, and death in offenders who have issues with alcohol and other drug use,” said lead author Professor Donald Weatherburn, from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney.

“Because MERIT is a pre-plea rather than a post-conviction program like the Drug Court, it has no presiding judge or prosecutors, no regime of random urine testing, and no punishment for non-compliance.”

“The current study shows, however, that it is no less capable in reducing drug-related crime and improving health outcomes.”

While MERIT has undergone several earlier evaluations, Professor Weatherburn’s study is the largest and most robust evaluation of the program to date.

It included more than 22,400 defendants who participated in the diversion program from 2012 to 2017 and whose criminal justice records were linked to health databases.

What is MERIT?

MERIT was introduced as a pilot program in 2000 and is available at 75 of the 137 Local Courts in NSW via referral from a magistrate, solicitor or police, as well as self-referral.

It is open to defendants who have a treatable AOD problem, are eligible for bail (or bail is not required), and have not committed a strictly indictable or sexual assault offence.

The program provides a range of AOD treatment services, such as counselling, residential rehabilitation and withdrawal management, while court matters are adjourned.

At completion, the magistrate dealing with the case is provided with a report from the MERIT team about client progress and any recommendations for future treatment.

What did the study show?

Compared to defendants who did not take part in the diversion program, Professor Weatherburn and colleagues found that MERIT participants were 21% less likely to reoffend in the following 12 months, and 27% less likely to receive a prison sentence.

They also found that those who entered MERIT had 33% lower risk of death from any cause but at the same time, higher rates of healthcare seeking such as ambulance callouts and hospital or ED admissions.

Professor Weatherburn said this finding could simply be due to exposure to AOD treatment itself being a launchpad for further engagement with health services.

“This would explain the paradoxical result of increased healthcare utilisation, yet fewer deaths. Participation in MERIT overcomes a range of potential barriers or resistance to accessing treatment for AOD use and other physical and mental health needs,” he said.

“Once engaged in treatment, their fear of stigma and additional health services may be reduced, and they might also be encouraged by service providers and peers to seek further help.”

Quotes attributable to the Attorney General of NSW, the Hon. Michael Daley:

“Programs like MERIT are important to alleviate pressure on the criminal justice system by breaking the cycle of substance abuse and reoffending.”

“Offenders who participate in drug and alcohol treatment under MERIT are less likely to end up in jail or back before the courts.

“The NSW Government will continue to invest in prevention and diversion to reduce offending and keep the community safe.”

-ENDS-


Contact details:

NDARC media contact: Kemal Atlay, 0401 713 850 | ndarc.media@unsw.edu.au

AGO media contact: Georgie Moore, 0439 419 465

For reference:When reporting on drugs and alcohol, we encourage consultation of the Mindframe guidelines on Communicating about alcohol and other drugs’and ‘Communicating about suicide, and the ‘Language Matters guide published by the NSW Users and AIDS Association. 

We also encourage inclusion of the following helpline information in all reporting:

People can access free and confidential advice about alcohol and other drugs by calling the National Alcohol and Other Drug Hotline on 1800 250 015.

More from this category

  • Medical Health Aged Care
  • 29/03/2025
  • 06:30
Dementia Australia

Join us today for the Bunbury Memory Walk & Jog

What: Dementia Australia’s Bunbury Memory Walk & Jog    When: Saturday, 29 March from 9:00am   Who: People who have been impacted by dementia, their family, friends and carers.   Where: Bunbury Surf Club, Bunbury   Dementia Australia spokespeople and local residents are available for interview. Photos and video of previous Memory Walk & Jog events for publication are available for use. For more information visit: www.memorywalk.com.au Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for…

  • Contains:
  • Medical Health Aged Care
  • 28/03/2025
  • 21:11
Organon & Co.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

SHANGHAI, China & JERSEY CITY, N.J.–BUSINESS WIRE– Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA)…

  • Contains:
  • Medical Health Aged Care
  • 28/03/2025
  • 17:11
Curium

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotopeBrings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chainPARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey.The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates, for Prostate Cancer…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.